Drug Profile
Research programme: thrombosis therapies - Elusys Therapeutics/University of Pennsylvania
Alternative Names: tPA-HPLatest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Elusys Therapeutics
- Class
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 20 Apr 2022 EluSys Therapeutics has been acquired by Heat Biologics
- 30 Mar 2004 Preclinical trials in Thrombosis in USA (unspecified route)